Skip to main content
UniHealth

Doctor search

Arun Kumar Arumugam Raajasekar, MD

Hematology/Oncology · Mountain View

NPI 1801143722

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
2
1 carrier
Office
1

Offices

1 location · El Camino Health Medical Network LLC · 202 clinicians in this group

Looking this up.

Hospitals listed: El Camino Health · Stanford Health Care · Yuma Regional Medical Center. That is not proof they admit you there this week.

Plans that list them

2 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Raajasekar’s office at (650) 988-8338 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
Anthem Full Dual Advantage Aligned (HMO D-SNP)Anthem Blue CrossListedOct 3, 2026
Anthem Medicare Advantage (HMO-POS)Anthem Blue CrossListedOct 3, 2026

Hospitals they work in

3 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend it
    Overall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Yuma Regional Medical CenterYuma, AZAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Yuma Regional Medical CenterPatients rate it 3 of 5 · 63% would definitely recommend it
    Overall rating: 2 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 223.03 (174.74 to 271.32) · 70 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.118, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health

Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at El Camino Health
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.291BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.393BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.96 (0.12 to 1.79) · 2,340 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.02 (0.76 to 1.28)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths167.38 (125.03 to 209.73) · 96 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.6 · 68 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.1 · 185 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths11.8 · 200 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths8.9 · 814 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths13 · 842 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 361 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.6 · 4,633 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.34) · 11,474 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.27 (0.1 to 0.45) · 11,626 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.14 (1.39 to 4.9) · 2,814 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths2 (0.61 to 3.39) · 1,327 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.11 (0.8 to 3.43) · 2,641 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths9.39 (4.18 to 14.6) · 1,287 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths6.57 (3.47 to 9.68) · 1,308 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths2.14 (0.71 to 3.57) · 827 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.6 (0.05 to 1.15) · 9,460 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4.5 · 122 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.993No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.706No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.376No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits15.5 · 218 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19.5 · 962 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits3.8 · 200 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-17 · 922 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits18.6 · 860 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18.7 · 827 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.1 (4.5 to 8.2) · 313 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits13.4 (10.6 to 16.5) · 313 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6.1 · 144 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.7 · 237 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.8 (10 to 16.1) · 1,639 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.9 (0.8 to 1.1) · 1,619 casesNo differentJan 2024 – Dec 2024

What patients said (1,535 patients answered, 22% of those asked)

Patient survey stars by topic at El Camino Health
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information3
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at El Camino Health
Room was "always" clean75%
Nurses "always" communicated well79%
Doctors "always" communicated well81%
Staff "always" explained61%
Yes, staff "did" give patients this information86%
Yes, staff "did" give patients information about help after discharge86%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand75%
Nurses "always" listened carefully76%
Nurses "always" treated them with courtesy and respect87%
"Always" quiet at night47%
"YES", patients would definitely recommend the hospital80%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms86%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Yuma Regional Medical Center

Behind the star rating — Deaths: 0 better, 6 the same, 2 worse of 8 measures. Safety: 1 better, 7 the same, 0 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Yuma Regional Medical Center
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths223.03 (174.74 to 271.32) · 70 casesWorseJul 2022 – Jun 2024
Clostridium Difficile (C.Diff)Infections0.118BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.49 (0.53 to 2.45) · 1,120 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.91 (0.59 to 1.24)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths4 · 84 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths11.8 · 154 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths13.4 · 302 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths12.3 · 456 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths17.2 · 627 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths16 · 296 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths4.8 · 3,722 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.21 (0 to 0.42) · 5,914 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.23 (0.03 to 0.42) · 6,115 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths2.42 (0.37 to 4.48) · 1,577 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.43 (0 to 3.04) · 438 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.1 (0.65 to 3.55) · 1,494 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths10.77 (3.99 to 17.55) · 451 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.6 (1.75 to 9.45) · 415 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.63 (0.16 to 3.1) · 329 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.37 (0 to 1.06) · 4,890 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 26 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.765No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.901No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.621No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.825No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.4 · 405 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits21.8 · 661 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-9.4 · 291 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits36.5 · 506 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits7 · 644 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits17.9 · 939 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.1 (4.5 to 8.3) · 327 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.6 (9.8 to 15.8) · 327 casesNo differentJan 2024 – Dec 2024
Rate of readmission for CABGUnplanned return visits12.3 · 93 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.1 · 216 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits14 (11.2 to 17.3) · 2,778 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.2 (0.9 to 1.4) · 940 casesNo differentJan 2024 – Dec 2024

What patients said (1,342 patients answered, 22% of those asked)

Patient survey stars by topic at Yuma Regional Medical Center
Cleanliness4
Nurse communication2
Doctor communication2
Communication about medicines2
Discharge information3
Overall hospital rating2
Quietness3
Recommend hospital3
Share of patients giving the best answer at Yuma Regional Medical Center
Room was "always" clean73%
Nurses "always" communicated well73%
Doctors "always" communicated well72%
Staff "always" explained53%
Yes, staff "did" give patients this information83%
Yes, staff "did" give patients information about help after discharge82%
Doctors "always" explained things so they could understand66%
Doctors "always" listened carefully70%
Doctors "always" treated them with courtesy and respect79%
Patients who gave a rating of "9" or "10" (high)62%
Staff "always" explained new medications66%
Nurses "always" explained things so they could understand67%
Nurses "always" listened carefully69%
Nurses "always" treated them with courtesy and respect82%
"Always" quiet at night52%
"YES", patients would definitely recommend the hospital63%
Staff "always" explained possible side effects39%
Yes, staff "did" give patients information about possible symptoms83%

Original Medicare doctor bills

$135,723

Medicare paid this office $135,723 for 434 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)158$55,203$108
Return visit (30+ min)279$45,532$68
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's291$10,138$13
New patient visit (60+ min)70$9,173$131
Short return visit (20+ min)109$6,145$44
See all 8 services
Every Original Medicare service billed
Long return visit (40+ min)158$55,203$108
Return visit (30+ min)279$45,532$68
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's291$10,138$13
New patient visit (60+ min)70$9,173$131
Short return visit (20+ min)109$6,145$44
New patient visit (45+ min)38$3,813$100
Initial hospital care with moderate level of medical decision making at least 75 minutes16$2,259$133
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes13$1,213$61

Who their Medicare patients are

434 Original Medicare patients in 2024. Average age 77 · Women 36% · Also on Medicaid 13% · Health risk score 1.98. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 75% · Cancer 60% · Chronic kidney disease 36% · Diabetes 35% · Coronary heart disease 35% · Heart failure 24% · COPD 22% · Atrial fibrillation 21% · Depression 20% · Stroke 13% · Dementia 8%.

The office billed $291,408, Medicare allowed $180,170 and paid $135,723; for 2,303 services of 17 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20244342,303771.98$291,408$135,723
20233831,169772.01$198,893$93,074
20223831,282751.90$237,313$109,707
20213781,317752.03$243,443$114,908
2020285948751.94$157,843$71,183
2019151282751.84$48,865$22,478

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 5 services

Original Medicare services billed in 2023
Return visit (30+ min)227$41,705$71
Long return visit (40+ min)112$27,480$107
New patient visit (60+ min)60$8,238$137
Short return visit (20+ min)120$7,815$47
New patient visit (45+ min)53$5,162$97

2022: 5 services

Original Medicare services billed in 2022
Long return visit (40+ min)134$54,382$110
Return visit (30+ min)207$27,016$71
New patient visit (60+ min)87$11,546$133
Short return visit (20+ min)148$9,297$44
New patient visit (45+ min)27$2,715$101

2021: 9 services

Original Medicare services billed in 2021
Long return visit (40+ min)159$51,118$114
Return visit (30+ min)207$28,838$72
New patient visit (60+ min)79$11,097$140
Short return visit (20+ min)144$10,520$50
New patient visit (45+ min)38$3,503$92
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes22$2,472$99
Initial hospital care with moderate level of medical decision making at least 75 minutes14$2,215$158
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or15$691$26
Short return visit13$373$29

2020: 9 services

Original Medicare services billed in 2020
Return visit (30+ min)168$23,157$60
Long return visit (40+ min)105$17,816$88
New patient visit (60+ min)87$11,241$129
Initial hospital care with moderate level of medical decision making at least 75 minutes24$4,334$161
New patient visit (45+ min)41$3,914$95
Telephone medical discussion with physician, 21-30 minutes51$3,706$63
Short return visit (20+ min)60$2,705$38
Telephone medical discussion with physician, 11-20 minutes33$1,432$40
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes11$802$57

2019: 5 services

Original Medicare services billed in 2019
Return visit (30+ min)57$6,422$62
Long return visit (40+ min)56$5,830$87
New patient visit (60+ min)37$4,879$132
New patient visit (45+ min)18$1,819$101
Short return visit (20+ min)24$1,081$40

Medicaid work

$44,397 in 2024

Medicaid paid $44,397 for 2,538 billed services this clinician did in 2024, up to 50 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)351$23,468
Return visit (30+ min)453$16,236
Short return visit (20+ min)144$4,376
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established)150$317
Pain severity quantified; no pain present (COA) (ONC)466$0
Medication list documented in medical record (COA)205$0
Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM)17$0
Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD)232$0
Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD)43$0
Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM)100$0
Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM)323$0
Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM)54$0
Medicaid work by year
20242,5381250$44,397
20232,104946$39,091
20221,361938$39,064
2021667432$26,696
2020185226$6,920
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Return visit (30+ min)486$19,167
Long return visit (40+ min)226$14,786
Short return visit (20+ min)197$5,138
Pain severity quantified; no pain present (COA) (ONC)412$0
Medication list documented in medical record (COA)143$0
Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD)237$0
Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD)12$0
Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM)38$0
Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM)353$0

2022

Largest Medicaid services in 2022
Long return visit (40+ min)395$24,470
Return visit (30+ min)290$9,385
Short return visit (20+ min)215$5,209
Pain severity quantified; no pain present (COA) (ONC)49$0
Medication list documented in medical record (COA)67$0
Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD)108$0
Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD)12$0
Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM)210$0
Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM)15$0

2021

Largest Medicaid services in 2021
Long return visit (40+ min)245$13,414
Return visit (30+ min)247$9,117
Short return visit (20+ min)159$3,011
New patient visit (45+ min)16$1,155

2020

Largest Medicaid services in 2020
Return visit (30+ min)171$6,800
Short return visit (20+ min)14$120

Drugs they prescribed that Part D paid

$4,976,642

Pharmacies billed $4,976,642 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 3% of their Part D prescriptions (52 of 1,530) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.

1,215 generic and fewer than 11 brand-name prescriptions · $4,976,642 in drug cost · 61 antibiotic prescriptions to 50 people · 25 antipsychotic prescriptions to people over 65.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Xtandi130$1,768,259$13,602
Cabometyx46$1,101,174$23,939
Pomalyst15$357,020$23,801
Abiraterone Acetate147$269,289$1,832
Nubeqa17$230,872$13,581
See all 34 drugs
Every Part D drug this clinician prescribed
Xtandi130$1,768,259$13,602
Cabometyx46$1,101,174$23,939
Pomalyst15$357,020$23,801
Abiraterone Acetate147$269,289$1,832
Nubeqa17$230,872$13,581
Inlyta11$213,626$19,421
Eliquis26$15,797$608
Enoxaparin11$2,457$223
Prochlorperazine Maleate133$1,793$13
Ondansetron119$1,735$15
Prednisone155$1,116$7
Dexamethasone61$1,102$18
Potassium Chloride21$946$45
Hydroxyurea28$772$28
Triamcinolone Acetonide14$647$46
Tamsulosin14$618$44
Oxybutynin Chloride Er22$399$18
Olanzapine25$338$14
Oxycodone33$336$10
Venlafaxine Hcl Er14$267$19
Famotidine24$259$11
Duloxetine13$229$18
Diphenoxylate-Atropine15$229$15
Bicalutamide11$225$20
Acyclovir14$217$16
Levothyroxine26$200$8
Nitrofurantoin Mono-Macro16$192$12
Gabapentin18$171$10
Lidocaine Hcl Viscous20$145$7
Sertraline34$135$4
Levofloxacin24$88$4
Losartan13$53$4
Furosemide11$50$5
Folic Acid14$41$3

Year by year

Part D prescribing by year
20241,5302683% (52)None$4,976,642
20231,2782124% (52)None$5,154,057
20228841585% (40)None$2,192,983
20215721092% (12)17%$1,441,767
202048283None13%$999,483
201911243None13%$140,498
2018471730% (14)None$1,263
2017923141% (38)None$8,449
20166318NoneNone$5,768
201514NoneNone0%$250
201411NoneNoneNone$312
201325110% (0)None$4,638

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 28 drugs

Part D drugs prescribed in 2023
Xtandi120$1,683,897$14,032
Cabometyx29$693,796$23,924
Abiraterone Acetate131$587,418$4,484
Pomalyst22$506,821$23,037
Inlyta17$330,058$19,415
Revlimid12$224,671$18,723
Afinitor11$214,960$19,542
Jakafi11$196,394$17,854
Nubeqa15$173,234$11,549
Eliquis24$24,836$1,035
Imatinib Mesylate14$18,445$1,318
Ondansetron125$2,104$17
Prochlorperazine Maleate116$1,873$16
Dexamethasone56$1,036$18
Prednisone116$910$8
Oxycodone36$561$16
Potassium Chloride11$557$51
Hydroxyurea24$520$22
Gabapentin13$454$35
Tamsulosin15$276$18
Pantoprazole14$220$16
Famotidine18$204$11
Levothyroxine11$197$18
Acyclovir13$190$15
Omeprazole16$147$9
Sertraline24$145$6
Levofloxacin15$112$7
Sulfamethoxazole-Trimethoprim24$62$3

2022: 24 drugs

Part D drugs prescribed in 2022
Pomalyst24$502,628$20,943
Xtandi26$355,964$13,691
Revlimid14$271,697$19,407
Abiraterone Acetate52$247,527$4,760
Nubeqa17$231,418$13,613
Scemblix11$218,585$19,871
Imatinib Mesylate23$17,099$743
Eliquis21$14,921$711
Ondansetron97$2,439$25
Dexamethasone85$2,263$27
Prochlorperazine Maleate97$1,718$18
Prednisone68$675$10
Bicalutamide16$590$37
Potassium Chloride13$546$42
Hydroxyurea20$378$19
Oxycodone29$352$12
Acyclovir23$292$13
Fluconazole13$255$20
Gabapentin14$166$12
Omeprazole15$135$9
Levofloxacin11$131$12
Sertraline11$127$12
Famotidine18$85$5
Sulfamethoxazole-Trimethoprim15$39$3

2021: 13 drugs

Part D drugs prescribed in 2021
Revlimid30$494,833$16,494
Abiraterone Acetate41$245,243$5,982
Xtandi16$205,260$12,829
Votrient12$124,468$10,372
Imatinib Mesylate24$22,919$955
Dexamethasone56$1,488$27
Ondansetron50$888$18
Prochlorperazine Maleate49$634$13
Hydroxyurea18$573$32
Prednisone38$377$10
Pantoprazole23$336$15
Acyclovir17$209$12
Omeprazole16$79$5

2020: 11 drugs

Part D drugs prescribed in 2020
Revlimid19$287,281$15,120
Xtandi20$246,989$12,349
Abiraterone Acetate50$210,584$4,212
Votrient12$116,053$9,671
Imatinib Mesylate13$14,540$1,118
Dexamethasone47$1,050$22
Ondansetron32$844$26
Prochlorperazine Maleate32$548$17
Prednisone60$435$7
Famotidine16$159$10
Levofloxacin12$117$10

2019: 2 drugs

Part D drugs prescribed in 2019
Prochlorperazine Maleate11$126$11
Prednisone12$73$6

2017: 1 drug

Part D drugs prescribed in 2017
Morphine Sulfate Er13$766$59

Money from drug and device companies

$942 in 2025

Industry payments by year
202512$942$942
202322None$95
202211None$62
202111None$20
201911None$21

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
TerSera TherapeuticsMargenza$942
2 payments
  • Consulting for Margenza · 2025-03-11 · $628
  • Consulting for Margenza · 2025-02-10 · $314
See all 2 published payments
Every published payment
TerSera TherapeuticsConsulting · 2025-03-11Margenza$628
TerSera TherapeuticsConsulting · 2025-02-10Margenza$314
See earlier years (2023, 2022, 2021, 2019)

2023: $95

Payments by company in 2023
AstraZeneca Pharmaceuticals LPLynparza$71
1 payment
  • Education for Lynparza · 2023-04-06 · $71
Karyopharm TherapeuticsXpovio$24
1 payment
  • Education for Xpovio · 2023-02-03 · $24

2022: $62

Payments by company in 2022
Janssen BiotechDarzalex$62
1 payment
  • Meals for Darzalex · 2022-03-03 · $62

2021: $20

Payments by company in 2021
Kite PharmaNone$20
1 payment
  • Education · 2021-01-18 · $20

2019: $21

Payments by company in 2019
GenzymeCablivi$21
1 payment
  • Meals for Cablivi · 2019-11-21 · $21

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
AstraZeneca UK Limited · A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2025Their institution$68,070
Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Phase III Multi-Center Study of Azacitidine With Or Without Mbg453 for the Treatment of Patients With Intermediate, High Or Very High Risk Myelodysplastic Syndrome (Mds) As Per Ipss-R, Or Chronic Myelomonocytic Leukemia-2 (Cmml-2) · 2023Their institution$59,983
AstraZeneca UK Limited · A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2024Their institution$49,639
Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Phase III Multi-Center Study of Azacitidine With Or Without Mbg453 for the Treatment of Patients With Intermediate, High Or Very High Risk Myelodysplastic Syndrome (Mds) As Per Ipss-R, Or Chronic Myelomonocytic Leukemia-2 (Cmml-2) · 2024Their institution$44,338
AstraZeneca Pharmaceuticals LP · A Phase III Randomized Open-Label Sponsor-Blinded Multicenter Study of Durvalumab in Combination With Tremelimumab Lenvatinib Given Concurrently With Transarterial Chemoembolization (Tace) Compared To Tace Alone in Patients With Locoregional Hepatocellular Carcinoma (Emerald-3) · 2025Their institution$35,184
Janssen Research & Development, LLC · Biomarker Study To Determine Frequency of Dna Repair Defects in Men With Metastatic Prostate Cancer · 2021Their institution$27,434
AstraZeneca Pharmaceuticals LP · A Phase III Randomized Open-Label Sponsor-Blinded Multicenter Study of Durvalumab in Combination With Tremelimumab Lenvatinib Given Concurrently With Transarterial Chemoembolization (Tace) Compared To Tace Alone in Patients With Locoregional Hepatocellular Carcinoma (Emerald-3) · 2023Their institution$23,969
AstraZeneca UK Limited · A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2023Their institution$22,382
AstraZeneca Pharmaceuticals LP · A Phase III Randomized Open-Label Sponsor-Blinded Multicenter Study of Durvalumab in Combination With Tremelimumab Lenvatinib Given Concurrently With Transarterial Chemoembolization (Tace) Compared To Tace Alone in Patients With Locoregional Hepatocellular Carcinoma (Emerald-3) · 2024Their institution$18,297
Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Phase III Multi-Center Study of Azacitidine With Or Without Mbg453 for the Treatment of Patients With Intermediate, High Or Very High Risk Myelodysplastic Syndrome (Mds) As Per Ipss-R, Or Chronic Myelomonocyt · 2025Their institution$12,597
Janssen Research & Development, LLC · Biomarker Study To Determine Frequency of Dna Repair Defects in Men With Metastatic Prostate Cancer · 2023Their institution$2,000
Janssen Research & Development, LLC · Biomarker Study To Determine Frequency of Dna Repair Defects in Men With Metastatic Prostate Cancer · 2022Their institution$1,163

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
82.4 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1801143722
Licence
KY 49139
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RH0003X (207RH0003X)
Mailing address
2400 S Avenue A, Yuma, AZ, 85364
NPI first listed
2012-08-09
NPI last updated
2026-02-12
NPI record certified
2026-02-12

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 815 Pollard Rd, Los Gatos, CA, 95032